SQLite Web: event_store.db

Update row 129354 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-18T03:05:05.644967+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:1f19740ad8532d68","evidence_event_ids":["evt_edf027d0d1e6"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-160320.txt","as_of":"2026-04-18T03:05:05.644967+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-160320.txt","company":"Tango Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-160320.txt","article_chars":2343,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_6fccdcdf9df8b68a","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-160320.txt","content_type":"text/plain","enriched_at":"2026-04-18T03:29:20.892607+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"DEFA14A","final_url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-160320.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-160320.txt","source_event_id":"evt_edf027d0d1e6","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEFA14A","fp":"a1ffece8e7ceb19a","kind":"sec_filing","published_at":"20260417","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-17","June 4, 2026","May 21, 2026"],"entities":[{"asset_class":"equity","name":"Tango Therapeutics, Inc.","relevance":"high","symbol":"","type":"issuer"}],"event_type":"listing","information_gaps":["The specific purpose of the DEFA14A (e.g., whether it is definitive additional materials or other category) is not fully specified in the provided text beyond the cover-page checkboxes.","The actual proposal descriptions for items 1a/1b/1c are not included in the provided excerpt\u2014only the \u201cFor\u201d indications are shown.","No financial guidance or financial implications are disclosed in the provided text.","The \u201cAmendment No.\u201d field is blank in the excerpt, so the amendment sequence is unknown.","No prior known state is provided in the prompt, so the \u201cwhat changed vs prior state\u201d cannot be determined from the given information."],"key_facts":["The document is a Schedule 14A proxy statement (proxy materials).","Form type is DEFA14A.","The filing indicates it is for a shareholder meeting to be held on June 4, 2026.","The notice states shareholders can view the proxy statement and annual report online at www.ProxyVote.com or request free paper/email copies.","The notice includes a request deadline of May 21, 2026 for receiving paper/email copies.","The text shows voting recommendations/positions labeled \u201cBoard Recommends\u201d with items 1a, 1b, and 1c marked \u201cFor\u201d (as displayed in the overview).","The filing includes standard proxy statement cover-page checkboxes (e.g., definitive proxy statement/additional materials) but the specific amendment number is shown as blank (\u201cAmendment No. \u201d)."],"numeric_claims":[{"label":"Shareholder meeting date","value":"June 4, 2026"},{"label":"Copy request deadline","value":"May 21, 2026"}],"primary_claim":"Tango Therapeutics, Inc. filed Form DEFA14A (Schedule 14A proxy statement) on 2026-04-17/18, with shareholder meeting materials for a meeting to be held on June 4, 2026.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"Tango Therapeutics, Inc. filed a Schedule 14A proxy statement on Form DEFA14A. The filing provides notice/overview of proposals for a shareholder meeting scheduled for June 4, 2026.","topics":["SEC filing","proxy statement","Schedule 14A","shareholder meeting notice","voting proposals"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEFA14A \u00b7 Tango Therapeutics, Inc. \u00b7 Filed 20260417","ticker":"TNGX","tickers":["TNGX"],"title":"TNGX filed DEFA14A","url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-160320.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel